Barclays Upgrades Humacyte (NASDAQ:HUMA) to Hold

Humacyte (NASDAQ:HUMA) was upgraded by investment analysts at Barclays to a “hold” rating in a report released on Wednesday, Zacks reports.

Other research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Humacyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. HC Wainwright increased their target price on Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Thursday, June 11th. TD Cowen cut their price target on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a report on Wednesday, June 17th. Benchmark reduced their price target on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research report on Thursday, August 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research note on Friday, October 2nd. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $5.68.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $0.45 on Wednesday. The firm has a market capitalization of $124.20 million, a PE ratio of -0.91 and a beta of 2.44. The company has a quick ratio of 5.74, a current ratio of 6.21 and a debt-to-equity ratio of 2.07. The company has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $0.76. Humacyte has a twelve month low of $0.44 and a twelve month high of $1.90.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The business had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.04 million. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. Equities analysts forecast that Humacyte will post -0.4 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new position in shares of Humacyte in the second quarter worth $4,700,000. BlackRock Inc. bought a new stake in Humacyte during the second quarter valued at $3,777,000. GSA Capital Partners LLP bought a new stake in Humacyte during the second quarter valued at $785,000. HBK Investments L P purchased a new position in Humacyte during the second quarter worth about $617,000. Finally, Wealth Effects LLC purchased a new position in Humacyte during the second quarter worth about $542,000. 44.71% of the stock is owned by institutional investors.

About Humacyte

Humacyte, Inc is a biotechnology company developing and manufacturing bioengineered human tissues for use in regenerative medicine. Its technology platform is designed to produce off-the-shelf, implantable tissues that can be stored and transported for use when needed, potentially reducing reliance on tissue obtained directly from patients or human donors.

The company’s primary product is SYMVESS, an acellular tissue-engineered vascular graft designed to replace or repair damaged blood vessels.